All In Biotech

Drug Trial Radar · NCT06938529

A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function

A Phase I Pharmacokinetic Study of VCT220 in Subjects With Varying Degrees of Hepatic Impairment and Normal Hepatic Function

Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Apr 18, 2025

Primary completion

Jul 15, 2025

Study completion Jul 25, 2025

Sponsor

Lead sponsor
Vincentage Pharma Co., LtdIndustry
Sponsor type
Industry
First posted
Apr 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, non-randomized study to assess how VCT220 is absorbed, distributed, metabolized, and eliminated after a single oral dose. The study includes three groups: subjects with mild hepatic impairment (Child-Pugh Class A), subjects with moderate hepatic impairment (Child-Pugh Class B), and healthy subjects matched by gender, age, and body mass index (BMI). It will also explore the relationship between baseline liver function measures and the pharmacokinetic (PK) parameters of VCT220, to support appropriate dosing recommendations for patients with liver impairment.

Conditions

  • Obesity, Overweight

Interventions

  • VCT220Drug

    Small molecule GLP-1RA tablet, film coated

  • PlaceboDrug

    VCT220 Placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak Plasma Concentration (Cmax) of VCT220Time frame: Predose up to 72 hours postdose (D1 to D4)
  2. Area Under the Serum Concentration Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of VCT220Time frame: Predose up to 72 hours postdose (D1 to D4)
  3. Area Under the Serum Concentration Curve From Time 0 to Infinity(AUC0-inf) of VCT220Time frame: Predose up to 72 hours postdose (D1 to D4)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Suzhou University

    Suzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.